Lifecare ASA appoints Petter Nielsen as Chief Financial Officer

Bergen, Norway, 25 February 2026 -- Lifecare ASA (LIFE), a MedTech company developing next-generation implantable continuous glucose monitoring (CGM) technology, announces the appointment of Petter Nielsen as Chief Financial Officer (CFO). Nielsen will assume the position on 1 April 2026.

Nielsen succeeds Renete Kaarvik, who will step down from her role as CFO with her last working day on 31 March 2026.

Petter Nielsen brings extensive financial and capital markets experience from listed growth companies and international industrial groups. He most recently served as Group Chief Executive Officer of Gexcon AS (2022--2025), having previously held the position as Group Chief Financial Officer in the same company. Prior to that, he served as CFO of BerGenBio ASA, where he played a central role in the company's listing on the Oslo Stock Exchange in 2017 and in raising significant equity and grant funding. He has also held senior finance roles in Vryhof/Deep Sea Mooring and Ernst & Young Transaction Advisory Services.

Nielsen holds an MSc in Auditing and an MSc in Economics and Business Administration from the Norwegian School of Economics (NHH) and is a State Authorised Public Accountant.

Joacim Holter, CEO of Lifecare, comments: "Petter brings strong financial leadership experience from publicly listed growth companies and complex industrial organisations. His background in capital markets, regulatory reporting and strategic financing will be highly valuable as Lifecare moves into its next phase of clinical development and prepares for commercial scale-up."

Holter continues: "On behalf of the Board and management team, I would also like to thank Renete for her important contributions to Lifecare during a transformative period for the company, including strengthening our financial structure and supporting key development milestones."

For further information, please contact: Joacim Holter, CEO Tel: +47 400 59 040 Email: joacim.holter@lifecare.no

About us Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

Contacts For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information has been submitted pursuant to the Securities Trading Act § 5-12 and MAR Article 17. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-02-25 07:00 CET.